- Home
- RLMD vs CEPF Comparison
RLMD vs CEPF Comparison
Compare RLMD & CEPF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RLMD | CEPF |
|---|---|---|
| Founded | 2004 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 661.9M | 593.2M |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | RLMD | CEPF |
|---|---|---|
| Price | $6.69 | $10.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $12.40 | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 55.5K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $13,070.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $96.45 |
| Revenue Growth | ★ 154.83 | N/A |
| 52 Week Low | $0.55 | $10.09 |
| 52 Week High | $8.00 | $10.67 |
Technical Indicators
Market Signals| Indicator | RLMD | CEPF |
|---|---|---|
| Relative Strength Index (RSI) | 47.20 | 54.83 |
| Support Level | $6.17 | $10.33 |
| Resistance Level | $7.46 | $10.65 |
| Average True Range (ATR) | 0.45 | 0.02 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 60.47 | 71.67 |
Price Performance
Historical ComparisonAbout RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.
About CEPF Cantor Equity Partners IV Inc. Class A Ordinary Shares
Cantor Equity Partners IV Inc is a blank check company.